An interventional study of Omnipod 5 System and Omnipod 6 System in Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, sponsored by Insulet Corporation. Recruiting at 11 sites in United States. Open to participants aged 14 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Insulet Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States — 344 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.
Among the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 986th largest by planned enrollment of the 2,960 interventional ones that give a count, is one of 157 that started in 2026, is one of 1,241 with no phase, reaches primary completion later than 207 of the 477 other live ones, and was the 3,230th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →344 of the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
Pfizer · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
Rahul Sachdeva · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 14 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,307 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 425 · Phase 2 465 · Phase 3 613 · Phase 4 300
First in 1976; this study’s year is marked. 157 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 2,960 interventional studies, 128 across the 336 observational. Of the 2,650 that completed or were terminated, 1,165 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,489 of 3,307 have an industry lead sponsor. The 10 most frequent:
Insulet Corporation is the lead sponsor of 23 studies on the registry; 5 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 8 (47%) have results posted.
Insulet Corporation has 6 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
187 of the studies in Diabetes Mellitus, Type 2 with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06731075Phase 3Oramed, Ltd.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | 2027-04-25 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 187 to your calendar (.ics) → With an account.
Among the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.
Following a 2-week standard therapy phase for baseline data collection, participants will be randomly assigned to the order in which they receive Omnipod 6 or Omnipod 5.
After completion of the first 13-week period, participants will cross-over to the opposite system for an additional 13 weeks. An optional 4-week extension will be offered to all participants to assess the response of the Omnipod 6 System with restricted boluses
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Omnipod 5 System
Device: Omnipod 6 System
The Omnipod 5 System with the study CGM
The Omnipod 6 System with the study CGM
Time in Range 70-180 mg/dL
Change in CGM percent time 70-180 mg/dL compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Time <54 mg/dL
Change in CGM percent time \<54 mg/dL compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Time <70 mg/dL
Change in CGM percent time \<70 mg/dL compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Time >180 mg/dL
Change in CGM percent time \>180 mg/dL compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Time in Range 70-140 mg/dL
Change in CGM percent time 70-140 mg/dL compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
HbA1c
Change in HbA1c (%) between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Mean sensor glucose
Change in mean CGM glucose mg/dL compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Time >250 mg/dL
Change in CGM percent time \>250 mg/dL compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Total boluses per day
Total blues per day will be compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Total daily insulin per kg and total insulin delivered via automation
Total daily insulin per kg and total insulin delivered via automation will be compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Percentage of time in automated mode
Percentage of time in automated mode will be compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Percentage with HbA1c <7.0% and <7.5%
Percentage with HbA1c \<7.0% and \<7.5% will be compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Percentage with >= 70% time in range
Percentage with \>= 70% time in range will be compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Percentage with >= 50% time in range
Percentage with \>= 50% time in range will be compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Diabetes treatment satisfaction
Patient Reported Outcome with treatment period comparison and baseline to Omnipod 6
Time frame: 13 weeks
System Usability
Patient Reported Outcome Survey evaluated at the end of each 13-week period
Time frame: 13 weeks
System Opinion
Patient Reported Outcome Survey evaluated at the end of each 13-week period
Time frame: 13 weeks
Health Related Quality of Life (HR-QOL)
Patient Reported Outcome Survey with treatment period comparison and baseline to Omnipod 6
Time frame: 13 weeks
Hypoglycemia confidence
Patient Reported Outcome Survey with treatment period comparison and baseline to Omnipod 6
Time frame: 13 weeks
Missed Meal - Peak glucose
Peak glucose 4-hours post-prandial compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Missed Meal - AUC
AUC 4-hours post-prandial compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Missed Meal - Time in Range
Time in Range 4-hours post-prandial compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Missed Meal - Percentage of Time > 180 mg/dL
Percentage of Time \> 180 mg/dL 4-hours post-prandial compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Missed Meal - Percentage of Time > 250 mg/dL
Percentage of Time \> 250 mg/dL 4-hours post-prandial compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Missed Meal - Percentage of Time <54 mg/dL
Percentage of Time \<54 mg/dL (NI margin of 0.5%) 4-hours post-prandial compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Missed Meal - Percentage of Time <70 mg/dL
Percentage of Time \<70 mg/dL (NI margin of 0.5%) 4-hours post-prandial compared between Omnipod 6 and Omnipod 5
Time frame: 13 weeks
Number of severe hypoglycemic events
Time frame: 13 weeks
Number of DKA or HHS events
Time frame: 13 weeks
Other related serious adverse events
Time frame: 13 weeks
Unanticipated adverse device effects
Time frame: 13 weeks
Reportable device-related adverse events
Time frame: 13 weeks
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Feb 2027, 9 months after the start.
Of 177 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's planned 9 months is below that.
Counting every sponsor, half of 2,249 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.